{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:25:54Z","timestamp":1791555954735,"version":"4.3.4"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Glucagon-like peptide 1 receptor agonists (GLP1-RAs) reduce cardiovascular events and mortality in type 2 diabetes. Limited data are available on diabetes treatment after solid organ transplantation. We aimed to explore the effect of GLP1-RAs on cardiovascular outcomes in transplanted recipients with diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We extracted data on adult transplant recipients (kidney, lungs, liver, heart) insured in a large health maintenance organization. Death-censored patients with diabetes treated with GLP1-RAs were matched with nonusers. The primary outcome was a composite of major cardiovascular events (MACEs): a nonfatal cardiac event (myocardial infarction, stable\/unstable angina, coronary bypass, and coronary angiography), ischemic stroke and all-cause mortality. Secondary outcomes were MACE or peripheral vascular disease (MACE-PVD), and all-cause mortality. Safety outcomes included biliopancreatic adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>We included 318 patients (69% males, average age 58.3\u2005\u00b1\u200511.0 y) with a 3.1-y median follow-up. The incidence of MACE was 101 of 1000 patient-years in GLP1-RAs users compared with 134 of 1000 in controls (hazard ratio [HR] 0.46; 95% confidence interval [CI], 0.27-0.78). GLP1-RAs similarly reduced the risk of MACE-PVD (HR 0.53; 95% CI, 0.33-0.88) and the risk of all-cause mortality (HR 0.39; 95% CI, 0.18-0.84). Biliopancreatic adverse events occurred less in GLP1-RA users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Transplant recipients with diabetes who used GLP1-RAs had lower risks for MACE and all-cause mortality. These results may profoundly implicate the daily management of posttransplant recipients with diabetes, a population with a high prevalence of cardiometabolic risk factors and cardiovascular death. Transplant patients are usually excluded from randomized controlled trials and, hence might be undertreated with disease-modifying drugs. Larger prospective studies are needed in this unique population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000004945","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:01:49Z","timestamp":1708041709000},"page":"e121-e128","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":28,"title":["Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus"],"prefix":"10.1097","volume":"108","author":[{"given":"Idit","family":"Dotan","sequence":"first","affiliation":[{"name":"Institute of Endocrinology, Diabetes and Metabolism, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel."},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Rudman","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Diabetes and Metabolism, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel."},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Turjeman","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"Research Authority, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Akirov","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Diabetes and Metabolism, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel."},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Steinmetz","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"Institute of Nephrology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronya","family":"Calvarysky","sequence":"additional","affiliation":[{"name":"Pharmacy, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel."},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Diker Cohen","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Diabetes and Metabolism, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel."},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.numecd.2020.12.030","article-title":"Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: a network meta-analysis of randomized, active comparator-controlled trials.","volume":"31","author":"Mannucci","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.118.033898","article-title":"Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial.","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","article-title":"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.","volume":"18","author":"Leiter","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/dom.14079","article-title":"The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of the LEADER and SUSTAIN 6 trials.","volume":"22","author":"Leiter","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","article-title":"Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors.","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1475-2840-13-49","article-title":"Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.","volume":"13","author":"Rizzo","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/db14-1149","article-title":"Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment.","volume":"64","author":"Balestrieri","year":"2015","journal-title":"Diabetes"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-8587(15)00387-3","article-title":"Post-transplantation diabetes\u2014state of the art.","volume":"4","author":"Sharif","year":"2016","journal-title":"Lancet Diab Endocrinol"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"e2920","DOI":"10.1002\/dmrr.2920","article-title":"New onset diabetes after kidney transplantation is associated with increased morta.lity\u2014a retrospective cohort study.","volume":"33","author":"Cooper","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"e130770","DOI":"10.1172\/jci.insight.130770","article-title":"Tacrolimus- and sir.olimus-induced human beta cell dysfunction is reversible and preventable.","volume":"5","author":"Dai","year":"2020","journal-title":"JCI Insight"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2337\/db05-1220","article-title":"Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4.","volume":"55","author":"Ranta","year":"2006","journal-title":"Diabetes"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1677\/jme.1.01655","article-title":"Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs.","volume":"34","author":"D\u2019Amico","year":"2005","journal-title":"J Mol Endocrinol"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.3390\/ijms20133152","article-title":"Management of diabetes mellitus in normal renal function, renal dysfunction and renal transplant recipients, focusing on glucagon-like peptide-1 agonist: a review based upon current evidence.","volume":"20","author":"Tsai","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/TP.0b013e31826e592e","article-title":"Calcineurin inhibition and new-onset diabetes mellitus after transplantation.","volume":"95","author":"Chakkera","year":"2013","journal-title":"Transplantation"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2337\/dc15-2383","article-title":"GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes.","volume":"39","author":"Halden","year":"2016","journal-title":"Diabetes Care"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/dom.13619","article-title":"Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients.","volume":"21","author":"Singh","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/dom.13964","article-title":"Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: a retrospective study.","volume":"22","author":"Singh","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1097\/TXD.0000000000000971","article-title":"The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients.","volume":"6","author":"Kukla","year":"2020","journal-title":"Transplant Direct"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1016\/j.transproceed.2021.08.042","article-title":"Institutional experience with new antidiabetic drugs in kidney transplant.","volume":"53","author":"Yugueros Gonzalez","year":"2021","journal-title":"Transplant Proc"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.transproceed.2018.03.087","article-title":"Management of diabetes mellitus with glucagonlike peptide-1 agonist liraglutide in renal transplant recipients: a retrospective study.","volume":"50","author":"Liou","year":"2018","journal-title":"Transplant Proc"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/lt.23950","article-title":"High early cardiovascular mortality after liver transplantation.","volume":"20","author":"VanWagner","year":"2014","journal-title":"Liver Transpl"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/lt.22468","article-title":"Cumulative risk of cardiovascular events after orthotopic liver transplantation.","volume":"18","author":"Albeldawi","year":"2012","journal-title":"Liver Transpl"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/kisup.2015.2","article-title":"United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease.","volume":"5","author":"Collins","year":"2015","journal-title":"Kidney Int Suppl"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/TP.0b013e3181caeead","article-title":"Reduction in cardiovascular death after kidney transplantation.","volume":"89","author":"Pilmore","year":"2010","journal-title":"Transplantation"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/tri.12413","article-title":"Cardiovascular morbidity and mortality after kidney transplantation.","volume":"28","author":"Stoumpos","year":"2015","journal-title":"Transpl Int"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/TP.0000000000003224","article-title":"Cardiac mortality in kidney transplant patients: a population-based cohort study 1988-2013 in Australia and New Zealand.","volume":"105","author":"Wyld","year":"2021","journal-title":"Transplantation"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/bmj.326.7388.509","article-title":"Prognosis after heart transplantation: transplants alone cannot be the solution for end stage heart failure.","volume":"326","author":"Anyanwu","year":"2003","journal-title":"BMJ"},{"key":"R32-20250604","first-page":"549","article-title":"Long-term outcome following heart transplantation: current perspective.","volume":"7","author":"Wilhelm","year":"2015","journal-title":"J Thorac Dis"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5500\/wjt.v5.i4.183","article-title":"Cardiovascular risk factors following renal transplant.","volume":"5","author":"Neale","year":"2015","journal-title":"World J Transplant"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transplant"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"e13794","DOI":"10.1111\/ctr.13794","article-title":"Cardiac allograft vasculopathy: insights on pathogenesis and therapy.","volume":"34","author":"Lee","year":"2020","journal-title":"Clin Transplant"},{"key":"R38-20250604","first-page":"CD013650","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.","volume":"10","author":"Kanie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"R39-20250604","first-page":"121","article-title":"Consequences of recipient obesity on postoperative outcomes in a renal transplant: a systematic review and meta-analysis.","volume":"14","author":"Sood","year":"2016","journal-title":"Exp Clin Transplant"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/MEG.0000000000002574","article-title":"The impact of obesity on postoperative complications and short-term survival after liver transplantation.","volume":"35","author":"Tejedor-Tejada","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs\u2014FDA and EMA assessment.","volume":"370","author":"Egan","year":"2014","journal-title":"N Engl J Med"},{"key":"R42-20250604","first-page":"206","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol (Torino)"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials.","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:05:48Z","timestamp":1749045948000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004945","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}